Frovocimab is a monoclonal antibody designed to target and inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein involved in regulating LDL cholesterol levels in the blood. By blocking PCSK9, frovocimab enhances the liver’s ability to remove LDL cholesterol from the bloodstream, leading to significant reductions in circulating LDL-C levels.

This antibody is primarily used in the development and validation of therapeutic and diagnostic platforms targeting hypercholesterolemia and related cardiovascular diseases. It serves as a reference standard in bioanalytical assays to evaluate the performance of anti-PCSK9 biosimilars and novel lipid-lowering agents. Its high specificity and well-characterized binding properties make it valuable in pharmacokinetic and pharmacodynamic studies during drug development.

Frovocimab also supports research into long-term cardiovascular risk reduction, especially in patients with statin intolerance or genetic lipid disorders such as familial hypercholesterolemia. Due to its role in modulating cholesterol metabolism, it contributes to advancing treatments aimed at preventing atherosclerotic cardiovascular disease.